2. Disease Areas
  3. Infection
  4. Bacterial Infection
  5. Klebsiella Pneumoniae Infection

Klebsiella Pneumoniae Infection

Klebsiella pneumoniae is a Gram-negative, encapsulated bacterium commonly present in human flora and natural environments, serving as a significant opportunistic pathogen responsible for severe hospital-acquired infections, particularly in immunocompromised individuals. It is a leading cause of nosocomial pneumonias and is frequently isolated from blood cultures in sepsis patients, contributing to both endemic and epidemic outbreaks. The organism's ability to acquire and transfer antibiotic resistance genes, especially to broad-spectrum cephalosporins and β-lactams, complicates treatment and contributes to high mortality rates. K. pneumoniae commonly causes infections in the lungs, urinary tract, bloodstream (sepsis), and liver, with infection severity often linked to underlying host immune deficiencies and the presence of indwelling medical devices. Its clinical significance has driven extensive research into its virulence factors, which play critical roles in pathogenesis, while emerging epidemiological data indicate rising infection rates beyond previously reported figures.

Klebsiella Pneumoniae Infection (17):

Art. -Nr. Produktname CAS. Nr. Reinheit Chemische Struktur
  • HY-164036
    Lolamicin 2930690-12-1 99.54%
    Lolamicin is an orally effective inhibitor that specifically targets the Gram-negative bacteria lipoprotein transport system LolCDE complex. It selectively inhibits the transmembrane transport of outer membrane lipoproteins by competitively binding to lipoprotein binding sites. Lolamicin destroys the integrity of the bacterial outer membrane, leading to cell death, and has both bactericidal and antibacterial activity. It has significant effects on multidrug-resistant Enterobacteriaceae pathogens (such as Escherichia coli and Klebsiella pneumoniae). Lolamicin can be used to inhibit the study of acute pneumonia, sepsis and other infections caused by Gram-negative bacteria.
    Lolamicin
  • HY-P1068
    Lysozyme 9001-63-2
    Lysozyme (Muramidase) is a conserved antimicrobial protein. Lysozyme exerts its bactericidal effect by hydrolyzing bacterial cell wall peptidoglycan (PG). Lysozyme plays an important role in limiting bacterial growth on mucosal surfaces and other sites, not only controlling potential pathogens but also limiting overgrowth of microbiota to prevent dysbiosis. Extracellular lysozyme can also degrade polymeric PG into soluble fragments, activate NOD receptors in mucosal epithelial cells, and lead to the secretion of chemokines and activating factors by neutrophils and macrophages.
    Lysozyme
  • HY-B1422
    9-Aminoacridine 90-45-9 99.35%
    9-Aminoacridine, a fluorescent probe, acts as an indicator of pH for quantitative determination of transmembrane pH gradients (inside acidic). 9-Aminoacridine is an antimicrobial. 9-Aminoacridine exerts its antimicrobial activity by interacting with specific bacterial DNA and disrupting the proton motive force in K. pneumoniae. 9-Aminoacridine is a HIV-1 inhibitor and inhibits HIV LTR transcription highly dependent on the presence and location of the amino moiety. 9-Aminoacridine inhibits virus replication in HIV-1 infected cell lines. 9-Aminoacridine is used as a Rifampin (RIF; HY-B0272) adjuvant for the multidrug-resistant K. pneumoniae infections.
    9-Aminoacridine
  • HY-157536
    SMT-738 2862851-15-6 98.47%
    SMT-738 is a bacterial bactericide. SMT-738 targets the small molecules responsible for lipoprotein transport in Enterobacteriaceae, causing abnormal lipoprotein localization and bacterial cell death. SMT-738 inhibits the growth of E. coli and K. pneumoniae. SMT-738 reduces bacterial loads in mouse models of urinary tract infection, bloodstream infection, and pulmonary infection caused by Enterobacterales. SMT-738 can be used in the research of Enterobacteriaceae infections, urinary tract infections, bloodstream infections, and pneumonia.
    SMT-738
  • HY-148790
    Pralurbactam 2163782-59-8 98.69%
    Pralurbactam (FL058) is a β-lactamase (Beta-lactamase) inhibitor. Pralurbactam enhances the antibacterial activity of Imipenem against Mycobacterium abscessus. Pralurbactam reduces the pulmonary bacterial load in neutropenic mice infected with Mycobacterium abscessus. Pralurbactam can be used in research related to infections caused by Mycobacterium abscessus complex, Escherichia coli, and Klebsiella pneumoniae.
    Pralurbactam
  • HY-123565
    TP-S1-68 120187-04-4
    TP-S1-68 (Compound 10) is a TIE-2 inhibitor with an IC50 of 3.65 μM. TP-S1-68 exhibits antibacterial activity against a variety of fungal and bacteria. TP-S1-68 serves as a starting compound for the further development of TIE-2 inhibitors. TP-S1-68 can be used in research related to solid tumors, bacterial infections and fungal infections.
    TP-S1-68
  • HY-P11720
    M104 peptide
    M104 peptide is an OXA-48 carbapenemase inhibitor and antibiotic potentiator. M104 peptide effectively blocks the binding and active site cavity of OXA-48. M104 peptide restores Meropenem (HY-13678)’s antibacterial activity against OXA-48-producing Klebsiella pneumoniae. M104 peptide can be used for the research of Carbapenem-resistant Klebsiella pneumoniae infection.
    M104 peptide
  • HY-180539
    JT71 380887-90-1 99.30%
    JT71 is an inhibitor of the transcriptional activator MrkH of type III fimbriae in Klebsiella pneumoniae. JT71 reduces the activity of the mrkA promoter in Klebsiella pneumoniae, effectively inhibiting the formation of biofilms by Klebsiella pneumoniae, while not affecting the cell's viability. JT71 can be used for research on Klebsiella pneumoniae infections.
    JT71
  • HY-182020
    LpxH-IN-3
    LpxH-IN-3 is a Klebsiella pneumoniae LpxH inhibitor with an IC50 of 0.17 μM. LpxH-IN-3 binds to the L-shaped hydrophobic binding pocket of Klebsiella pneumoniae LpxH, forms hydrogen bonds and other interactions with key residues, disrupts lipid A biosynthesis, and induces bacterial death. LpxH-IN-3 exhibits moderate antibacterial activity against Klebsiella pneumoniae and Escherichia coli. LpxH-IN-3 can be used for the research of klebsiella pneumoniae infection.
    LpxH-IN-3
  • HY-105560
    Cefcanel 41952-52-7
    Cefcanel is an orally active cephalosporin and antibacterial agent. Cefcanel inhibits growth of methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, Haemophilus influenzae, Moraxella catarrhalis. Cefcanel acts as a substrate hydrolyzed by TEM-1, TEM-3, and Moraxella Bro-1 beta-lactamases.
    Cefcanel
  • HY-180118
    Moxifloxacin prodrug-1 TFA
    Moxifloxacin prodrug-1 TFA (Compound 1e) is a Moxifloxacin (HY-66011A) prodrug and antibacterial agent. Moxifloxacin prodrug-1 TFA exhibits comparable potent activity as Moxifloxacin against E. coli, S. aureus, K. pneumoniae, A. baumannii, and P. aeruginosa. Moxifloxacin prodrug-1 TFA inhibits Mtb.
    Moxifloxacin prodrug-1 TFA
  • HY-181892
    LpxC-IN-17
    LpxC-IN-17 (Compound a5) is a non-covalent LpxC inhibitor and Antibacterial agent. LpxC-IN-17 chelates catalytic zinc ions and forms extensive non-covalent interactions within the LpxC active site, thereby functionally inhibiting the enzyme. LpxC-IN-17 exhibits antibacterial activity against Gram-negative pathogens including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. LpxC-IN-17 is applicable to research related to Gram-negative bacterial infections.
    LpxC-IN-17
  • HY-181939
    Antibacterial agent 329
    Antibacterial agent 329 (Compound 9c) is an antibacterial agent. Antibacterial agent 329 inhibits the activity of MraY. Antibacterial agent 329 exhibits antibacterial activity against Escherichia coli K12 and Bacillus subtilis W23 with a MIC of 16 μg/mL, but shows no activity against Pseudomonas fluorescens Pf-5. Antibacterial agent 329 exerts antibacterial activity against Acinetobacter baumannii 19606, Staphylococcus aureus MRSA USA300 JE2, Enterobacter cloacae 19434, Klebsiella pneumoniae 700603 and Enterococcus faecium 19434, with MIC values of 8, 8, 16-32, 16-32 and 16 μg/mL, respectively, while it shows no activity against Pseudomonas aeruginosa NCTC 13437.
    Antibacterial agent 329
  • HY-179632
    Antibacterial agent 311 2349248-62-8
    Antibacterial agent 311 (Compound 4f) is an antibacterial agent. Antibacterial agent 311 exhibits antibacterial activities against P. aeruginosa, S. aureus, E. coli, K. pneumonia, E. CTXM1, E. NDM1 with MICs of 0.8, 1, 1, 1, 0.7, 0.7 mg/mL.
    Antibacterial agent 311
  • HY-160762
    IMB-H4 524681-90-1
    IMB-H4 is an antibacterial agent and BamA binder. IMB-H4 disrupts BamA-BamD interaction by binding to BamA. IMB-H4 shows growth inhibition to Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
    IMB-H4
  • HY-B1422R
    9-Aminoacridine (Standard) 90-45-9
    9-Aminoacridine (Standard) is the analytical standard of 9-Aminoacridine. This product is intended for research and analytical applications. 9-Aminoacridine, a fluorescent probe, acts as an indicator of pH for quantitative determination of transmembrane pH gradients (inside acidic). 9-Aminoacridine is an antimicrobial. 9-Aminoacridine exerts its antimicrobial activity by interacting with specific bacterial DNA and disrupting the proton motive force in K. pneumoniae. 9-Aminoacridine is a HIV-1 inhibitor and inhibits HIV LTR transcription highly dependent on the presence and location of the amino moiety. 9-Aminoacridine inhibits virus replication in HIV-1 infected cell lines. 9-Aminoacridine is used as a Rifampin (RIF; HY-B0272) adjuvant for the multidrug-resistant K. pneumoniae infections.
    9-Aminoacridine (Standard)
  • HY-U00380
    Tigemonam 102507-71-1
    Tigemonam is an orally active monobactam antibiotic with a Ki of 0.86 μM against Enterobacter cloacae P99 β-lactamase and 50.8 μM against Escherichia coli TEM-1 β-lactamase. Tigemonam binds to penicillin-binding proteins 1a, 3, and 4, inhibits bacterial cell wall synthesis, and exhibits bactericidal activity against aerobic gram-negative bacteria including Enterobacteriaceae, Haemophilus influenzae, and Neisseria gonorrhoeae. Tigemonam resists hydrolysis by multiple β-lactamase enzymes, reduces bacterial load in systemic, pyelonephritic, lung, and thigh muscle infections in rodents, and shows minimal difference between minimum inhibitory and bactericidal concentrations. Tigemonam can be used for the research of gram-negative bacterial infections, acute pyelonephritis, lung infection, and thigh muscle infection.
    Tigemonam